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Harm reduction strategies
involve promoting a product
that has adverse health conse-
quences as a substitute for one
that has more severe adverse
health consequences. Smoke-
less tobacco low in nitrosamine
content offers potential bene-
fits in reducing smoking preva-
lence rates. Possible harm
arises from the potential for
such products to serve as a
gateway to more harmful to-
bacco products, public misin-
terpretation of “less harmful”
as “safe,” distraction from the
public health goal of tobacco
elimination, and ethical issues
involved in advising those mar-
keting these harmful products.
We offer a research agenda to
provide a stronger basis for
evaluating the risks and bene-
fits of smokeless tobacco as a
means of reducing the adverse




THE USE OF TOBACCO
products, especially cigarettes, re-
sults in exposure to hundreds of
chemicals, many of which have
adverse health consequences.
The primary agents of concern in
smoked tobacco are polycyclic
aromatic hydrocarbons, carbon
monoxide, nicotine, and N-nitroso
compounds, along with smaller
amounts of polonium, radon,
arsenic, and cadmium. Polycyclic
aromatic hydrocarbons are pro-
duced by the high temperatures
reached in the burning of to-
bacco. N-nitroso compounds, in-
cluding nitrosamines, are found
in tobacco leaves themselves,
may be formed to some extent
during combustion, and are
transported to cigarette smoke.
Smoked tobacco is the most
prevalent and harmful tobacco
product, with overwhelming
evidence showing substantially
increased risks of a variety of
cancers; chronic obstructive
pulmonary, cardiovascular, and
oral diseases; and adverse repro-
ductive outcomes.
Recognition by leaders in
some developed countries of
these well-documented harmful
consequences of smoking has re-
sulted in increasingly effective
actions, such as political action,
taken to curtail the epidemic of
tobacco-related diseases. Yet, the
epidemic continues unabated
and is even accelerating in many
parts of the world. Tools for com-
bating the epidemic include pub-
lic policies intended to discour-
age tobacco use through taxation
and restrictions on promotion,
media campaigns designed to
prevent smoking initiation and
encourage cessation, individual
counseling techniques1 and med-
ications designed to promote and
maintain smoking cessation,
modification of tobacco products
to reduce harmfulness, and sub-
stitution of less harmful for more
harmful products (e.g., pharma-




The underlying principle of
harm reduction is that a product
that has adverse health conse-
quences is promoted as a substi-
tute for one that has more severe
adverse health consequences.2
The addictive features of nicotine
are central to the problem of
continuing use of tobacco. Even
nicotine as a pure pharmaceuti-
cal agent has short-term adverse
cardiovascular effects, although it
has none of the health effects as-
sociated with other agents in cig-
arette smoke or smokeless to-
bacco. Smokeless tobacco
products offer a potential harm
reduction strategy for which the
magnitude of health risk to an in-
dividual user would be expected
to fall between pharmaceutical-
grade nicotine (1 of smokeless
tobacco’s constituents) and smok-
ing (which includes all the toxic
constituents of smokeless tobacco
as well as others).
The primary agents of concern






nicotine itself. Although the exact
magnitude of reduction in risk
gained from substituting use of
smokeless tobacco (particularly
a low-nitrosamine product) for
cigarette smoking is not easily
quantified, a panel of experts es-
timated reductions in total mor-
tality in the range of 90% to
95%.3 Despite such a large esti-
mated benefit relative to smok-
ing, important scientific and ethi-
cal questions arise.
Use of high-dose methadone
maintenance treatment among
heroin addicts has remained con-
troversial despite 40 years of
clear clinical evidence that it is
moderately effective in rehabili-
tating opiate injection drug users
and preventing the spread of
HIV/AIDS. The price of this
harm reduction is acceptance of
continued addiction to a narcotic.
Similar questions have been
raised with regard to needle ex-
change programs designed to
prevent the spread of HIV/AIDS
among injection drug users. Par-
allel concerns arise with the sub-
stitution of less harmful for more
harmful tobacco products: might
this practice “sanitize” or even
unintentionally initiate the harm-
ful behavior? Does accommodat-
ing the harmful behavior suggest
that society now condones or
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accepts it, discouraging more de-
finitive solutions?
In Sweden the widespread use
of Swedish snuff, called snus, a
moist smokeless tobacco product
placed under the upper lip, has
been viewed as a possible model
for successful harm reduction,4,5
although not without contro-
versy.6 Sweden has achieved the
lowest smoking prevalence rate
in all of Europe, approximately
17% of adult men in 2000; an
estimated 19% of adult men and
1% of adult women use snus
daily.5 Furthermore, snus appears
to be a component of successful
smoking cessation.7 The low
smoking prevalence rate and
high rate of use of snus in Swe-
den may be related, but this as-
sociation has not been estab-
lished with certainty.
As recommended in the Insti-
tute of Medicine report Clearing
the Smoke,8 manufacturers have
now begun to develop and mar-
ket tobacco products that reduce
but do not eliminate exposure to
tobacco-related toxicants. The re-
port also called for consumers to
be fully informed of the adverse
consequences associated with
these products and for surveil-
lance to be conducted on health
effects subsequent to marketing.
Star Scientific, a small tobacco
company located in Chester, Va,
began to market 2 smokeless to-
bacco products with very low
levels of tobacco-specific ni-
trosamines and sought expert ad-
vice to better define the health
risks associated with use of its
products relative to smoked and
conventional smokeless tobaccos.
The company sought answers to
the following questions: do
smokeless tobacco products pose
risks to health? If so, what is the
nature of these risks, are there
special populations at higher risk,
and how do the risks compare
with those of cigarette smoking?
Are there physical or chemical
characteristics of specific smoke-
less tobacco products or different
uses that influence health risks?
Star Scientific provided an un-
restricted grant to Best Practice
Project Management Inc, a con-
sulting and project management
company located in Bethesda,
Md, to convene a consensus con-
ference to respond to these ques-
tions. A panel was convened in
May 2003 with the agreement
that it would respond to the
questions and would, in addition,
prepare a report for publication
independent of the sponsor (the
present article). The panel con-
ducted a literature search on the
topic and enlisted a range of ex-
perts with and without previous








contain air- or fire-cured tobacco
that is powdered or ground for
use as nasal or oral snuff, cut and
grated for use as chewing or oral
snuff, or stripped and compacted
for use as chewing tobacco. Such
products may include sugars
(sucrose, fructose, sorbitol, mo-
lasses, dried fruit), water, sodium
chloride, ammonium chloride,
licorice, menthol, paraffin oil, and
glycerol. Tobacco-specific nitro-
samines in smokeless products
are derived from leaf nitrates
that were reduced to nitrites, pri-
marily via bacterial fermentation.
Nitrites and amines in the to-
bacco react to form nitrosamines
that are clearly carcinogenic in
animals and probably carcino-
genic in humans.9 Trace metals
occur at low levels and probably
do not contribute to carcinogene-
sis in the smokeless tobacco
products marketed in the United
States and Sweden.10
Certain smokeless tobacco
products have low levels of form-
aldehyde, and those that are
smoke-cured also have significant
amounts of polycyclic aromatic
hydrocarbons, some of which,
such as benzo[a]pyrene, are car-
cinogens.10 Swedish snus is com-
posed of air-cured and fire-cured
tobaccos. Since 1981, no fermen-
tation has been used in its pro-
duction, and a heating step
sharply reduces microorganism
content. Additives and flavors
presumed to be safe are used in
the process, and the net result is
a product low in tobacco-specific
nitrosamines (10 mg/kg or less).
The magnitude of the health
risk associated with smokeless
products appears to be associ-
ated with the type of tobacco
and method of cultivation used.
Greater potential for harm is as-
sociated with fire-curing (result-
ing in deposits of polycyclic aro-
matic hydrocarbons on the leaf),
bacterial contamination, fermen-
tation during production (which
may favor the activity of micro-
organisms that reduce nitrates
to nitrites, leading to formation
of nitrosamines),11 inclusion of
certain additives in Asian prod-
ucts (e.g., areca nuts),12 and par-
ticular methods of product stor-
age (some of which may promote
continued bacterial formation of
nitrosamines). Behavioral influ-
ences on health risks include
amount of smokeless tobacco
consumed and frequency of use,
length of application, surface of
application, oral hygiene, and
rates of salivating, swallowing,
and spitting. Risk associated with
use may be modified by other
exposures such as diet, alcohol
consumption, and genetics.13–15
Carcinogenicity
Evidence that smokeless to-
bacco, which includes moist and
dry snuff, causes oral cancer in
humans is persuasive, given bio-
logical plausibility, specificity for
buccal mucosa and gingiva (sites
of contact), and the strength and
consistency of epidemiological
evidence across populations and
geographic locations.16–18 The
carcinogens NNN and NNK are
found in the saliva of snuff dip-
pers, and measurements of uri-
nary excretions of NNK metabo-
lites have been found to be
similar among users of snuff and
chewing tobacco and smokers.10
Reducing the nitrosamine con-
tent of smokeless tobacco (as in
snus) should reduce carcinogenic-
ity. Nonetheless, nitrosamines can
be produced in vivo from nicotine
itself and from tobacco-specific or
other amines.9 Reports on the car-
cinogenicity of snus in the Scandi-
navian and other literature18–22
suggest minimal risk of oral or
other cancers among users. How-
ever, as is the case with any
smokeless tobacco product, snus
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contains carcinogenic nitro-
samines, albeit at markedly lower
levels than those found in the
types of smokeless tobacco used
in the United States and most
other parts of the world; pharma-
ceutical nicotine does not contain
these nitrosamines.23
American smokeless tobaccos
can be divided into chewing to-
bacco, moist snuff, and dry snuff.
In 1 review of different types of
smokeless tobacco24 that evalu-
ated 23 studies published be-
tween 1957 and 1998, no clear
epidemiological evidence was un-
covered that indicated chewing to-
bacco increases the risk of head or
neck cancer. There was evidence
of an increased risk of oral cancer
associated with use of American
dry snuff, but there were small or
no clear risks of oral cancer asso-
ciated with use of moist snuff, de-
spite the presence of elevated ni-
trosamine levels in such products.
Cardiovascular Disease
Smokeless tobacco use pro-
duces a much slower onset and
much lower peak concentration
of nicotine in the blood supply-
ing the heart and brain than does
smoked tobacco, even with the
same total daily dose of nicotine.
Use of chewing tobacco or snuff
for 30 minutes leads to a gradual
rise in blood nicotine concentra-
tion followed by a sustained level
of concentration that continues
for up to 2 hours.25,26 The sys-
temic dose from a single expo-
sure to snuff or chewing tobacco
is estimated at 2 to 3 mg.
Studies comparing cigarette
smoking, snuff use, and use of
chewing tobacco have demon-
strated qualitatively similar effects
on the sympathetic nervous sys-
tem from nicotine.26 For all 3
products, the heart rate is in-
creased, although its elevation is
sharper and persists for a shorter
interval with smoking than with
snuff, consistent with the time
course of blood concentrations.
During most of the day, circadian
heart rates are approximately
7 beats per minute higher among
those who smoke cigarettes,
chew tobacco, or use oral snuff
than among those who are
abstinent.
Epidemiological studies of snuff
users have revealed no increased
risk of myocardial infarction27 or
increased atherosclerosis28 rela-
tive to nonusers. Although the
acute nicotine-related effects of all
tobacco products and pharmaceu-
tical nicotine are essentially the
same, the risk of clinically signifi-
cant cardiovascular disease is
clearly linked to smoking and not
to use of smokeless tobacco.28
Similarly, risks associated with
chronic obstructive pulmonary
disease are a consequence of
smoking but not of smokeless
tobacco use.29
Oral Health Effects of
Smokeless Tobacco
In addition to cancers, oral
health concerns related to smoke-
less tobacco include leukoplakia,
gingivitis, periodontitis, and dental
caries as well as cosmetic con-
cerns such as tooth staining, mal-
odor, and tooth loss with resultant
disfigurement. Leukoplakia is
strongly associated with the use
and placement position of smoke-
less tobacco and appears and dis-
appears with changes in use.30 A
Swedish study of mucosal and
other leukoplakic lesions among
snuff dippers showed reversible
histological changes and sug-
gested that Swedish snus produces
less severe lesions than American
snuff.31
Gingivitis and periodontitis are
common infectious diseases in
which bacteria colonize the
tooth surface, with resulting
gingival (gum) inflammation; re-
cession from the tooth surface,
exposing the roots; and accompa-
nying destruction of the bony
sockets of the teeth (periodontitis).
Some data suggest that tobacco
products adversely influence
periodontitis-associated flora32,33
and host immune responses to
inflammatory agents.34 There is
no evidence of an association of
smokeless tobacco with recession
of the gums independent of pre-
existing gingivitis. However, peri-
odontitis is clearly more rapidly
destructive among smokers and
perhaps among smokeless to-
bacco users. Periodontitis also re-
sponds more poorly to treatment
in smokers.35,36
One study conducted in the
United States showed that caries
(decay) of the root surfaces of
teeth was associated with use of
chewing tobacco but not snuff.37
Amount of decay was associated
with intensity and duration of use
and was probably a function of
the high levels of sugar contained
in chewing tobacco products.
Reproductive Health
The primary reproductive
health concern with smokeless
tobacco is nicotine itself, which
has vasoconstrictive effects that
can have an adverse influence on
fetal growth and development. In
rodents, nicotine exposure during
pregnancy resulted in reduced
birthweights, increased fetal mor-
tality, abnormal bone develop-
ment, and reduced activity
levels.38 Among smokers, carbon
monoxide also contributes to ad-
verse effects on growth and brain
development.38,39
One study focusing on infant
birthweight suggested that
women given nicotine patches
usually continued to smoke but
smoked less, and those who
smoked less had improved birth-
weights.40 Few studies of repro-
ductive health among women
who use smokeless tobacco are
available from Western countries,
because historically not many
women of reproductive age have
used such products. Some re-
search has been conducted in
India among women using chew-
ing tobacco; although these stud-
ies are of limited relevance be-
cause of the differences between
that country’s products and those
used in the United States and
Sweden, there were indications
of increases in stillbirths41 and re-
ductions in birthweights among
the participants.41,42 A more re-
cent study of Swedish snus users
revealed decreases in birth-
weights and increased risks of
preterm delivery (relative risk
[RR]=1.6) and preeclampsia





A public health approach to
tobacco addiction should in-
clude preventing initiation of
November 2006, Vol 96, No. 11 | American Journal of Public Health Savitz et al. | Peer Reviewed | Health Policy and Ethics | 1937
 HEALTH POLICY AND ETHICS 
use, facilitating smoking cessa-
tion, and promoting abstinence
from all tobacco products by
current users. Policymakers un-
derstandably disagree on the
risks and benefits of harm re-
duction strategies aimed at those
who are unable (or unwilling) to
stop using tobacco products.
Any product that delivers nico-
tine confers health risks, yet
smoked tobacco clearly confers
far greater risks than smokeless
tobacco. Reduction of nitro-
samine levels in smokeless to-
bacco should markedly reduce
carcinogenicity.
However, whereas scientists
and public health experts ac-
knowledge a gradient of harmful-
ness, the public may dichotomize
products and behaviors as
“harmful” or “safe.” Applying the
“harmful but safer” concept to
the use of smokeless tobacco in
comparison with active smoking
poses a challenge to health edu-
cators and advertisers. Overstate-
ment of harm could prevent
smokers from switching to
smokeless tobacco.44 Understate-
ment of harm could lead non-
users to adopt use of smokeless
tobacco. Thus, the issue is not
merely whether policymakers
can agree on the potential value
of risk reduction strategies but
whether, in practice, the “harm-
ful but safer” message can be ef-
fectively conveyed to the public.
The intense promotion of
smokeless tobacco products to
young men is clearly intended to
foster initiation of use among
this population. The legitimacy
of harm reduction is predicated
on effective targeting of active
smokers and users of smokeless
tobacco high in nitrosamine con-
tent. Ideally, a product should
not be promoted or adopted
among either nonusers of to-
bacco or active smokers capable
of quitting. The Swedish experi-
ence indicates that snus does not
serve as a gateway to smoking
and appears to have contributed
to dramatic declines in smoking
as its use increased,22 but the re-
sponse to such products may
well differ in the United States.
If it is not possible to isolate and
market to the group of smokers
who could benefit, there may be
net harm from these products.
Given the financial incentive to
market smokeless tobacco prod-
ucts on a wide scale, the success
of a public health–based harm
reduction strategy will depend
in part on effective regulation.
The complex regulatory environ-
ment affecting tobacco advertis-
ing and sales and the marketing
of nicotine delivery products is
applicable as well to the market-
ing of smokeless tobacco prod-
ucts low in nitrosamine content.
Restrictions on advertising and
sales to minors, reporting of con-
stituents, and mandatory warning
labels would be among the key
considerations.
If a harm reduction strategy is
adopted, it will require a clear
definition of relative health risks
associated with low-nitrosamine
smokeless tobacco products, per-
haps coupled with further limita-
tions on advertising of more dan-
gerous products. A comprehensive
strategy is needed from the out-
set to ensure that the product is
marketed solely as a harm reduc-
tion tool. The ultimate test of any
regulatory approach to these new
tobacco products is its impact on
public health; thus, careful docu-
mentation of patterns and conse-
quences of use is required.
Some public health advocates
note that harm reduction strate-
gies run counter to the ultimate
goal of a tobacco-free society,
confusing the public health mes-
sage advocating abstinence from
all forms of tobacco use. Further-
more, they argue, marketing one
tobacco product as a substitute
for another may divert attention
and resources from policies de-
signed to discourage or eliminate
use altogether. Weakening the po-
litical will to aggressively pursue
such proven strategies as increas-
ing cigarette taxes, restricting pub-
lic smoking, and enforcing age re-
strictions on purchasing tobacco
may be an unintended conse-
quence of promotion of harm re-
duction. Moreover, an attractive
substitute in the form of smoke-
less tobacco could discourage ac-
tive smokers from completely dis-
continuing their tobacco use.
A final concern facing re-
searchers and public health ad-
vocates is ethical: whether and
how to advise those who seek to
market smokeless tobacco prod-
ucts. Manufacturers of smokeless
tobacco would clearly be seeking
profits through sales of a harmful
product, albeit one that may
have net public health benefits.
These companies need scientific
expertise if they are to address
health concerns, devise market-
ing strategies consistent with the
goal of harm reduction, and
monitor the effectiveness of
those strategies. The long history
of dishonesty by the tobacco
industry and by some of the
researchers supported by that in-
dustry raises ethical concerns.
Proactively addressing the
concerns expressed here should
be helpful to policymakers and
corporations contemplating the
development and marketing of
harm reduction products. If these
issues can be raised objectively
in advance, in an open forum,
reputable scientists would have
the opportunity to contribute
their knowledge to policymakers,
who would benefit from access
to the best available information.
Despite much success in elimi-
nating tobacco use, we need
more, not fewer, tools in the
multifaceted effort to address
this public health issue. Moti-
vated current smokers who are
unable to quit should be a spe-
cific target audience for harm re-
duction strategies.
As a result of the limited effec-
tiveness of smoking cessation
programs, recalcitrant smokers
represent a sizable proportion of
tobacco users both in the United
States and around the world.
Smokeless tobacco products low
in nitrosamine content may rep-
resent a beneficial alternative for
this group of smokers who have
not been helped by other avail-
able tobacco control strategies.
QUESTIONS CONCERNING
SMOKELESS TOBACCO
Questions that need to be an-
swered about smokeless tobacco
products focus on whether these
products have a place in the
array of tobacco control tools.
We propose that the following
questions be addressed in re-
search efforts:
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• How do the constituents of
concern change between
manufacturer and consumer?
In the process of storage and
distribution, chemical changes
can occur that could lead to in-
creased levels of harmful com-
pounds,11 calling for evaluation
of the effects of storage time
and temperature after realistic
estimates of distribution and
storage have been taken into
account.
• What is the dose–response
relationship between specific
smokeless tobacco constituents
and health outcomes? Quantita-
tive uncertainties in such rela-
tionships call for additional toxi-
cological and epidemiological
research.
• What are the short- and long-
term clinical consequences of
switching from tobacco smok-
ing to use of smokeless tobacco
products? Although there are
abundant data to predict physi-
ological and clinical effects of
switching, detailed studies char-
acterizing cardiovascular, oral
health, and related effects
would improve the extent to
which consequences of changes
in patterns of tobacco use could
be accurately predicted at the
population level.
• What effect does use of smoke-
less tobacco products have on
the success of smoking cessa-
tion interventions? What is the
impact of using smokeless to-
bacco on amount of smoking
among continuing smokers?
Among current smokers who
are unlikely to discontinue use,
how effective is smokeless to-
bacco relative to pharmaceuti-
cal nicotine?
• What regulations are needed
to ensure that the marketing
and adoption of smokeless to-
bacco products yield public
health benefits (i.e., helping re-
calcitrant smokers quit) as op-
posed to producing harmful
outcomes (i.e., leading to use of
these products by nonsmokers
or those who could otherwise
quit smoking)?
• What are the demographic
characteristics and tobacco use
histories of those who are initi-
ating use of smokeless tobacco?
To what extent is marketing
leading to initiation of smoke-
less tobacco use among current
smokers, as intended, or adop-
tion by nonusers, possibly even
leading to the use of more dan-
gerous smokeless tobacco prod-
ucts or smoking? Research is
also needed to estimate the pro-
portion of active smokers who
would have quit smoking but
instead switched to a less harm-
ful smokeless tobacco product,
as opposed to the proportion
who would have continued
smoking but switched. The pro-
portion of current smokers who
continue to smoke and simply
add smokeless tobacco would
be of interest as well.
Although many important is-
sues remain unresolved, we be-
lieve that a harm reduction strat-
egy needs to be considered as
one of the elements of a broad
program aimed at tobacco con-
trol. Finally, it is our belief that
an effective harm reduction strat-
egy merits the same rigorous as-
sessment and critical evaluation
as any other policy intended to
advance public health.
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